Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | GBA1 | P04062 | 6/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.38 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25835931 | 0.91 | GBA1 (0.41) | DRD2GBA1EPHX2OPRM1FOLH1 | |
| SCHEMBL24894530 | 0.89 | EPHX2 (0.47) | DRD2GBA1EPHX2GGPS1 | |
| SCHEMBL22083577 | 0.88 | DRD2 (0.44) | DRD2GBA1EPHX2OPRM1FOLH1 | |
| SCHEMBL25835929 | 0.87 | ALDH1A1 (0.51) | DRD2GBA1EPHX2 | |
| SCHEMBL24894086 | 0.87 | DRD2 (0.47) | DRD2GBA1EPHX2GGPS1 | |
| SCHEMBL25978189 | 0.86 | GBA1 (0.48) | DRD2GBA1EPHX2GGPS1 | |
| SCHEMBL25835936 | 0.85 | DRD2 (0.42) | DRD2GBA1EPHX2OPRM1 | |
| SCHEMBL25978193 | 0.82 | DRD2 (0.43) | DRD2GBA1EPHX2FOLH1GGPS1 | |
| SCHEMBL26032013 | 0.81 | DRD2 (0.41) | DRD2GBA1EPHX2OPRM1FOLH1 | |
| SCHEMBL25495665 | 0.81 | DRD2 (0.37) | DRD2OPRM1FOLH1LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | DRD2 4154/4885GBA1 627/4885EPHX2 3168/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | DRD2 4285/4885GBA1 2176/4885EPHX2 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.